Eesti turba balneoloogiliste kasutamisvõimaluste uuring (III etapp) — Study of Balneological Uses of Estonian Peat (Stage III)
Key Findings
- First clinical trial of Estonian balneological peat for hand osteoarthritis
- 23 patients started, 19 completed (4 dropouts: 1 skin sensitivity/vitiligo, 1 BP reaction, 1 malaise/suspected allergy, 1 subacute synovitis worsening)
- Treatment: finely ground peat in sealed bags heated to 42°C, hands immersed 30 min, 10 sessions over 2 consecutive weeks
- Pain (ICF scale): 53% positive — 4 pain-free, 6 reduced, 8 unchanged, 1 no prior pain
- Joint mobility (finger III-palm distance): 33% improvement, average reduction 1.4 cm in 7 patients
- Grip function improved in multiple patients
- Joint stiffness: 7 resolved, 1 reduced, 6 unchanged, 5 no prior issue
- All studied peat layers contain bioactive humic substances up to 60% of organic matter
- Estonian therapeutic peat reserves estimated at 920,000 tonnes across 7 deposits
- Contains comprehensive literature review by Übner on humic substance biological effects: TPP immunomodulation, antiviral activity, anticoagulant effects, collagen stabilization, desmutageenic activity
- Sodium humate has analgesic and anti-inflammatory effects; ammonium humate 2× more effective anti-inflammatory than acetylsalicylic acid
- Estrogenic activity of peat humic substances 5,000× greater than estradiol standard
- Ethics approval: Tallinn Medical Research Ethics Committee decision #1027
The first clinical trial of Estonian balneological peat — Stage III of a three-part research program that began with geological mapping (Stage I) and chemical characterization (Stage II). Conducted at East Tallinn Central Hospital Rehabilitation Center from July to November 2007, with ethics approval from the Tallinn Medical Research Ethics Committee (decision #1027). This report is the foundation of Estonia’s therapeutic peat credential.
The Trial
23 patients with bilateral hand osteoarthritis (Heberden’s nodes, Bouchard’s nodes, erosive interphalangeal arthritis, and first carpometacarpal joint arthritis) enrolled. Treatment: finely ground peat sealed in bags, heated to 42°C, hands immersed for 30 minutes, 10 sessions over two consecutive weeks. 19 patients completed; 4 dropped out — one each for skin sensitivity/vitiligo, blood pressure reaction, malaise/suspected allergy, and subacute synovitis worsening. Dropouts are documented in full, which is more transparent than many comparable studies.
Results
| Outcome | Result |
|---|---|
| Pain (ICF scale) | 53% positive — 4 pain-free, 6 reduced, 8 unchanged, 1 no prior pain |
| Joint mobility (finger III–palm distance) | Average 1.4 cm reduction in 7 patients (33% improvement) |
| Grip function | Improved in multiple patients |
| Joint stiffness | 7 resolved, 1 reduced, 6 unchanged, 5 had no prior stiffness |
This is a single-arm cohort — no control group, no blinding. The improvements are clinically meaningful, but cannot be isolated from natural disease fluctuation or placebo effect with this design alone.
Literature Review Component
Chapter 4, authored by Monika Übner, contains an independent literature survey of peat biological effects that is valuable in its own right. Key findings referenced: Tolpa Peat Preparation (TTP) immunomodulatory effects in human peripheral blood cells; antiviral mechanisms of humic acids against HSV and HIV; anticoagulant and fibrinolytic properties; collagen stabilization; and desmutagenic activity. Two notable data points from this chapter: sodium humate shows analgesic and anti-inflammatory effects, and ammonium humate is reported to be twice as effective an anti-inflammatory as acetylsalicylic acid (aspirin). The estrogenic activity of peat humic substances is reported as 5,000× that of estradiol — a figure that has since attracted scientific discussion and should be read with caution pending confirmation in independent studies.
Context
This trial was small and uncontrolled — it was designed to establish feasibility and safety of Estonian peat in a clinical setting, not to generate definitive efficacy data. That purpose it served: it confirmed that Estonian peat is safe and tolerable for therapeutic use, produced measurable clinical outcomes, and provided the groundwork for the international publications that followed (Orru 2010, 2011).